CD19 and congenital rubella syndrome: Finally, treatment with the tyrosine hydroxylase inhibitor metyrosine, which blocks the synthesis of catecholamines, protected mice from lethal complications of CRS induced by CD19-targeting CAR T cell infusion [67].